From:  Bile-based liquid biopsy in cholangiocarcinoma: current evidence, clinical applications and future directions

 Pre-analytical requirements and published findings by bile-derived biomarker class.

Analyte classBile volume used (published studies)Critical pre-analytical variablesKey published findingsOutstanding gaps
cfDNA/ctDNA1 mL (Arechederra et al. [9]); 3–6 mL (Li et al. [13]); ≥ 10 mL (Han et al. [14])Early cell/debris removal; centrifugation protocol; tube type; storage temperature and duration; extraction method (bile-specific vs. plasma kits)Preservation tubes maintain stability ≤ 10 days at RT and ≤ 2 months at 4°C [18]; 3D-BCF method recovers full fragment-size distribution [17]; stability up to 7 h at RT shown for ctDNA [14]No standardised minimum volume; optimal centrifugation parameters not established across laboratories; cfDNA yield vs. volume relationship not quantified in bile
DNA methylationNot consistently reportedSimilar to cfDNA; input DNA quality critical for ddPCR assaysddPCR methylation assays (CDO1, CNRIP1, SEPT9, VIM) validated in bile from PSC cohorts [19, 20]Methylation-specific extraction requirements in bile not validated; freeze-thaw effects unstudied
microRNA/non-coding RNANot consistently reportedEV isolation method (ultracentrifugation vs. precipitation vs. SEC); RNA extraction kit; freeze-thaw cycles; time to freezingEV-protected RNA more stable than free RNA in bile [15, 22, 23]; bile miRNA profiles distinguish BTC from benign disease [23]No bile-specific RNA extraction validation; EV isolation inconsistently reported; miRNA stability in bile not formally assessed
EVsNot consistently reportedIsolation method (ultracentrifugation, SEC, precipitation); bile viscosity and bile salt interference; storage temperature; MISEV2023 reporting standards [39]EV cargo can distinguish malignant from benign biliary disease [22, 23, 25, 27]; phosphatidylcholine identified in CCA-derived EVs [27]Heterogeneous isolation methods; inconsistent nomenclature; no bile-specific EV characterisation standards; all studies small (n = 7 malignant, n = 15 total in Muraki et al. [27])
Proteomics/lipidomics/metabolomics40–50 mL (bile proteomics [29]); not stated for most lipidomic studiesImmediate freezing; bacterial contamination; bile dilution; freeze-thaw cycles; instrument batch effectsBileLipid classifier (6-lipid panel, AUC 0.828–0.956 across cohorts) [30]; bile microbiome + metabolite signatures distinguish CCA from PSC [32]; POSTN identified via bile proteomics [29]Complex analytical pipelines; susceptible to ERCP duodenal flora contamination [32]; external validation lacking; no consensus on sample preparation

cfDNA: cell-free DNA; ddPCR: droplet digital polymerase chain reaction; ERCP: endoscopic retrograde cholangiopancreatography; EV: extracellular vesicle; MISEV2023: Minimal Information for Studies of Extracellular Vesicles 2023; PSC: primary sclerosing cholangitis; RT: room temperature; SEC: size-exclusion chromatography; BTC: biliary tract cancer.